EWEdvard Wigren

Edvard Wigren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edvard Wigren has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A high-throughput screening dataset of small-molecule inhibitors across human DNA glycosylases

    by Alice Eddershaw, Bjørn Dalhus, Opher Gileadi, Susanne Gräslund, İrŞil Güneş, Thomas Helleday, Kang-Cheng Liu, Olga Loseva, Vu To Nakstad, Hilde Nilsen, et al.

    The base excision repair pathway removes small base lesions from DNA and is initiated in humans by one of eleven DNA glycosylases with overlapping substrate specificities. Despite their central role in genome maintenance and transcription, systematic datasets describing small-molecule binders or inhibitors of DNA glycosylases are lacking. Here, through a collaborative effort across Scandinavia, we establish a high-throughput biochemical assay platform for human DNA glycosylases and use it to generate a systematic small-molecule screening dataset. A chemogenomic library was screened against nine glycosylases with assays of sufficient quality for hit identification, yielding primary screening and concentration-response data and identifying multiple previously unreported inhibitors. All primary and processed data, along with detailed assay protocols and metadata, are publicly available to support reuse in chemical biology, further compound optimization, assay development and comparative studies of DNA repair enzymes.

  • Open Access

    ABHD2 activity is not required for the non-genomic action of progesterone on human sperm

    by Madison Edwards, Alexandra Amaral, Eve M Carter, Oliver Arnolds, Karen Vester, Anna Thrun, Edvard Wigren, Evert Homan, Pauline Ribera, Kirsty Bentley, et al.

    STUDY QUESTION: Is the hydrolase ABHD2 required for progesterone-induced Ca2+ influx via CatSper and the resulting motility responses in human sperm? SUMMARY ANSWER: Progesterone-induced Ca2+ influx via CatSper and the resulting motility responses in human sperm do not require ABHD2 activity. WHAT IS KNOWN ALREADY: Sperm motility is tightly regulated by signalling pathways that are activated as sperm ascend the female reproductive tract, including progesterone triggering Ca2+ influx via the CatSper channel and inducing hyperactivated motility needed for fertilization. This process is thought to involve ABHD2, which may hydrolyze the endogenous CatSper inhibitor 2-arachidonoylglycerol (2-AG), thereby relieving inhibition and enabling calcium entry into the flagellum. STUDY DESIGN, SIZE, DURATION: Potent small molecule inhibitors of ABHD2 activity were synthesized, characterized, and used as tools to scrutinize the role of ABHD2 in activation of CatSper and regulation of sperm motility. PARTICIPANTS/MATERIALS, SETTING, METHODS: Derivatives of published ABHD2 inhibitors were optimized for in vitro potency and cellular activity and subsequently tested in human sperm motility and Ca2+ influx assays. MAIN RESULTS AND THE ROLE OF CHANCE: Progesterone does not activate ABHD2 in vitro. In addition, inhibition of ABHD2 in human sperm has no effect on progesterone-induced Ca2+ influx through CatSper nor on basal or progesterone-induced hyperactivated motility. This demonstrates that ABHD2 activity is, in fact, not required for the non-genomic action of progesterone on human sperm. LARGE SCALE DATA: None. LIMITATIONS, REASONS FOR CAUTION: We examined the effects of inhibition of the enzymatic activity of ABHD2. We cannot exclude that ABHD2 functions as a part of a larger multiprotein complex, in which it may play a structural role independent of its hydrolase activity. WIDER IMPLICATIONS OF THE FINDINGS: This study presents conclusive evidence that ABHD2 does not bind progesterone and that its hydrolase activity is not required for progesterone activation of CatSper and resulting changes in motility of human sperm. These results highlight the need for further research to elucidate the mechanism underlying the non-genomic action of progesterone on human sperm. STUDY FUNDING/COMPETING INTEREST(s): This publication is based on research funded by the Gates Foundation, reference IDs INV-040467 and ID INV-072213. The findings and conclusions contained within are those of the authors and do not necessarily reflect the positions or policies of the Gates Foundation. LT, CB, and TS were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—project numbers 329621271 (CRU326; CB, TS), and 404595355 (Research Training Group ‘Chemical biology of ion channels (Chembion)’; LT, TS). This work was funded by the German Federal Ministry of Education and Research (BMBF) within the framework of Contraception Research, grant numbers 01GR2501A and 01GR2502A. A.A., K.V., A.T., N.D., A.H., M.W., and R.L. are employees of Nuvisan ICB GMBH, Berlin, Germany. Nuvisan is a recipient of a Gates Foundation grant. A.A. is associate editor of Human Reproduction Open.


  • Open Access

    Sensitive detection of plasma interferon regulatory factor-5 (IRF5) by solid-phase proximity ligation assay validates IRF5 high and low subgroups in patients with systemic lupus erythematosus

    by N Karami, E Wigren, C Preger, R Gallini, I Gunnarsson, E Svenungson, S Gräslund, H Idborg

    Interferon regulatory factor 5 (IRF5) plays a central role in interferon-mediated inflammation and is implicated in autoimmune diseases, including systemic lupus erythematosus (SLE). Detecting IRF5 in plasma is challenging due to its low circulating levels, highlighting the need for a highly sensitive and quantitative assay. This study aimed to develop such an assay, validate the existence of previously identified IRF5 high and low subgroups in SLE, and support the potential of IRF5 as a biomarker in precision medicine. We established a solid-phase proximity ligation assay (SP-PLA) for IRF5 detection using a commercially available polyclonal antibody, which was benchmarked against two in-house recombinant antibodies. A linear calibration curve was generated using recombinant IRF5 protein (range 0.01-100 pg/µL), with a limit of detection between 0.01 and 0.05 pg/µL. EDTA-plasma samples from three SLE subgroups (n = 25 per group) were analysed. IRF5 was detectable in all SLE plasma samples using SP-PLA (mean 0.63 pg/µL; sd 1.92 pg/µL; maximum 13.54 pg/µL). The IRF5 high SLE subgroup showed significantly higher IRF5 plasma levels than the IRF5 low SLE subgroup (Dunn's post-hoc test, adjusted p < 0.05). The SP-PLA enabled sensitive and specific detection of low-level IRF5 in plasma and confirmed the presence of IRF5 high and low subgroups in SLE using a quantitative method. These findings support the potential of IRF5 as a biomarker, but validation in independent cohorts is required. The assay may facilitate patient stratification in future research and precision medicine approaches targeting the interferon pathway.

  • Open Access

    Anti-MDA5 monoclonal antibodies from patients with dermatomyositis - B cell characteristics and differential targeting of the helicase domains

    by Eveline Van Gompel, Marina Galesic, Nicolas Delaroque, Karolin Kern, Ragnhild Stålesen, Antonella Notarnicola, Deniz Demirdal, Monika Hansson, Annika van Vollenhoven, Edvard Wigren, et al.

    Objectives: Autoantibodies targeting melanoma differentiation associated protein 5 (MDA5) are strongly associated with dermatomyositis (DM) and may contribute to its pathogenesis. Here we aimed to investigate MDA5 + B cells, their phenotype and generate MDA5 monoclonal antibodies to assess their epitope specificity. Methods: MDA5-reactive B cells were captured from peripheral blood of patients with anti-MDA5 + DM (n=3) using an MDA5-fluorescent probe. B cell receptor (BCR) sequences were analysed from single-sorted B cells (n=240). Selected clones were re-expressed as IgG1 monoclonal antibodies (mAbs, n=23). Reactivity was assessed using recombinant MDA5 protein constructs, peptide epitope mapping, ELISA, western blot and a commercial line blot assay. Results: Of 240 anti-MDA5 + sorted B cells, 23 BCRs were re-expressed as mAbs, two of which showed high reactivity and specificity for MDA5. These antibody sequences originated from one CD19 + IgD - CD27 - CD38 + and one CD19 + IgD - CD27 + CD38 + IgG + B cell with low somatic hypermutation (SHM). Both mAbs had nanomolar apparent affinity and bound to sites within the helicase domains of the MDA5 protein but with distinct epitope recognition. Serology screening confirmed targeting of a linear epitope identified in the mAb studies. Conclusion: Our results show that anti-MDA5 + B cells recognize the helicase domains, which are the enzymatically active domains of the protein. These results have implications for understanding the etiopathology of anti-MDA5 + DM and development of new antigen-specific therapies.


  • Open Access

    A validated antibody toolbox for ALS research

    by Riham Ayoubi, Emma J. MacDougall, Ian McDowell, Michael S. Biddle, Bárbara T. Ferreira, CongYao Zha, Marie-France Dorion, Jay P. Ross, Sara González Bolívar, Vera Ruiz Moleón, et al.

    Many proteins associated with amyotrophic lateral sclerosis (ALS) remain poorly characterized, in part because validated reagents for protein-level studies are scarce. We previously established knockout (KO)-based antibody characterization workflows and showed that widely used antibodies against the ALS-associated protein C9orf72 lacked specificity (Laflamme et al., 2019), and subsequently scaled this framework to systematically benchmark research antibodies, revealing that up to 61% do not perform as recommended by manufacturers (Ayoubi et al., 2023). Here, we extend this approach by establishing the ALS-Reproducible Antibody Platform (ALS-RAP) to evaluate antibodies against proteins encoded by ALS risk genes. We characterized 303 antibodies targeting 33 ALS-associated proteins using KO-based antibody characterization workflows to identify high-quality reagents for common experimental applications. Using validated antibodies, we profiled protein levels across human induced pluripotent stem cell (iPSC)-derived and primary neurological cell types, revealing diverse cellular distributions and higher protein levels for several ALS-associated proteins in glial and immune populations. Together, ALS-RAP provides a validated antibody toolbox and protein expression resource for studying ALS-associated proteins, supporting the view that ALS genetics converges on multicellular disease mechanisms involving both neuronal and glial populations.

  • Open Access

    ABHD2 activity is not required for the non-genomic action of progesterone on human sperm

    by Madison Edwards, Alexandra Amaral, Eve M. Carter, Oliver Arnolds, Karen Vester, Anna Thrun, Edvard Wigren, Evert Homan, Pauline Ribera, Kirsty Bentley, et al.

    Study question: Is the hydrolase ABHD2 required for progesterone-induced Ca 2+ influx via CatSper and the resulting motility responses in human sperm? Summary answer: Progesterone-induced Ca 2+ influx via CatSper and the resulting motility responses in human sperm do not require ABHD2 activity. What is known already: Sperm motility is tightly regulated by signalling pathways that are activated as sperm ascend the female reproductive tract, including progesterone triggering Ca 2+ influx via the CatSper channel and inducing hyperactivated motility needed for fertilization. This process is thought to involve ABHD2, which may hydrolyse the endogenous CatSper inhibitor 2-arachidonoylglycerol (2-AG), thereby relieving inhibition and enabling calcium entry into the flagellum. Study design, size, duration: Potent small molecule inhibitors of ABHD2 activity were synthesized, characterized, and used as tools to scrutinize the role of ABHD2 in activation of CatSper and regulation of sperm motility. Participants/materials, setting, methods: Derivatives of published ABHD2 inhibitors were optimised for in vitro potency and cellular activity and subsequently tested in human sperm motility and Ca 2+ influx assays. Main results and the role of chance: Progesterone does not activate ABHD2 in vitro. In addition, inhibition of ABHD2 in human sperm has no effect on progesterone-induced Ca 2+ influx through CatSper nor on basal or progesterone-induced hyperactivated motility. This demonstrates that ABHD2 activity is, in fact, not required for the non-genomic action of progesterone on human sperm. Large scale data: none Limitations, reasons for caution: We examined the effects of inhibition of the enzymatic activity of ABHD2. We cannot exclude that ABHD2 functions as a part of a larger multiprotein complex, in which it may play a structural role independent of its hydrolase activity. Wider implications of the findings: This study presents conclusive evidence that ABHD2 does not bind progesterone and that its hydrolase activity is not required for progesterone activation of CatSper and resulting changes in motility of human sperm. These results highlight the need for further research to elucidate the mechanism underlying the non-genomic action of progesterone on human sperm. Study funding/competing interest(s): This publication is based on research funded by the Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Gates Foundation. LT, CB, and TS were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - project numbers 329621271 (CRU326; CB, TS), and 404595355 (Research Training Group “Chemical biology of ion channels (Chembion)’; LT, TS). This work was funded by the German Federal Ministry of Education and Research (BMBF) within the framework of Contraception Research, grant number 01GR2501A and 01GR2502A. A.A., K.V., A.T., N.D., A.H., M.W. and R.L. are employees of Nuvisan ICB GMBH, Berlin, Germany. Nuvisan is recipient of a Gates Foundation grant. A.A is associate editor of Human Reproduction Open.

  • Open Access

    Autoantibodies against the melanoma differentiation–associated protein 5 in patients with dermatomyositis target the helicase domains

    by Eveline Van Gompel, Deniz Demirdal, Catia Fernandes-Cerqueira, Begum Horuluoglu, Angeles Galindo-Feria, Edvard Wigren, Susanne Gräslund, Ellen De Langhe, Olivier Benveniste, Antonella Notarnicola, et al.

    Clinical observations in patients with dermatomyositis (DM) and autoantibodies against the melanoma differentiation–associated protein 5 (MDA5) suggest that the autoantibodies contribute to the pathogenesis of MDA5(+) DM. To gain insight into the role of the anti-MDA5 autoantibodies, we aimed to identify their binding sites on the different domains of the MDA5 protein. We developed an in-house ELISA to assess the reactivity against the MDA5 domains (conformational epitopes) in plasma (n = 8) and serum (n = 24) samples from MDA5(+) patients with varying clinical manifestations and disease outcomes. The reactivities were also assessed using western blot (linearized epitopes). An ELISA-based depletion assay was developed to assess cross-reactivity among the different MDA5 domains. All eight plasma samples consistently showed reactivity towards conformational and linearized epitopes on the helicase domains of the MDA5 protein. The ELISA-based depletion assay suggests that anti-MDA5 autoantibodies specifically target each of the three helicase domains. Twenty-two of the 24 serum samples showed reactivity in the in-house ELISA and all 22 displayed reactivity towards the helicase domains of the MDA5 protein. Our data revealed that the main immunogenic targets of anti-MDA5 autoantibodies from MDA5(+) patients are the helicase domains. Considering that the helicase domains are responsible for the enzymatic activity and subsequent triggering of an inflammatory response, our findings suggest that binding of anti-MDA5 autoantibodies could alter the canonical activity of the MDA5 protein and potentially affect the downstream induction of a pro-inflammatory cascade.


  • Open Access

    Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain

    by Aleksandra Szykowska, Yu Chen, Thomas B. Smith, Charlotta Preger, Jingjing Yang, Dongming Qian, Shubhashish M. Mukhopadhyay, Edvard Wigren, Stephen J. Neame, Susanne Gräslund, et al.


  • Open Access

    Generation and validation of recombinant antibodies to study human aminoacyl-tRNA synthetases

    by Charlotta Preger, Edvard Wigren, Elena Ossipova, Carolyn Marks, Johan Lengqvist, Camilla Hofström, Oskar Andersson, Per-Johan Jakobsson, Susanne Gräslund, Helena Persson